Metformin Hydrochloride Market Size, Share & Industry | 2030

Metformin Hydrochloride Market Size, Share & Industry | 2030

Segments - Metformin Hydrochloride Market By Type (Metformin Hydrochloride-Immediate Release, Metformin Hydrochloride-Extended Release), Distribution Channel (Hospital Pharmacy, Drug Store, Retail Pharmacy, Online Pharmacy), and Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022 – 2030

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-4782 | 4.1 Rating | 67 Reviews | 221 Pages | Format : PDF Excel PPT

Report Description


Metformin Hydrochloride Market Outlook

The global metformin hydrochloride market size was valued at USD 391.9 Million in 2021 and is projected to reach USD 572.9 Million by 2030, expanding at a CAGR of 4.4% during the forecast period, 2022 – 2030. The market growth is attributed to the growing prevalence of diabetic patients, cardiovascular disease, and obesity.

An MS/SS Vertical Vessel with Filter Leaves inside makes up the Pressure Leaf Filter. Growing adoption of a sedentary lifestyle resulted in an increase in the incidence of type 2 diabetes among the population of all age groups, which in turn boosts the consumption of metformin hydrochloride medication for treating type 2 diabetes diseases, which contributes to the market growth.

Metformin Hydrochloride Market Outlook

Metformin hydrochloride is an oral anti-hyperglycemic drug used for treating type 2 diabetes. Metformin hydrochloride is marketed under different brand names such as Glucophage and Fortamet. The metformin hydrochloride tablets are available in two forms namely, extended-release and immediate-release.

Metformin is an approved medicine for adults and children aged 10 and over. The metformin hydrochloride extended-release formula is approved for adults aged 18 and over. According to the American Diabetes Association's (ADA) Standards of Medical Care in Diabetes, metformin is the initial oral diabetes medicine for type 2 diabetes as it is safe and effective, and is expected to reduce the risk of cardiovascular disease.

Metformin Hydrochloride Market Dynamics

Major Driver 

Increasing type-2 diabetes patients world

Diabetes is primarily treated with metformin hydrochloride, which is expected to drive the market. The prevalence of diabetes is anticipated to rise globally, due to the changing lifestyle of people, starvation, and genetic abnormalities among people.

According to the World Health Organization (WHO), In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes.

The American Diabetes Association estimates that 71,000 deaths in the US occur each year due to diabetes. Around 537 million people across the world had diabetes in 2021. According to the International Diabetes Federation, over 10% of the adult population (642 million) is expected to suffer from diabetes by 2040.

Increasing risk of cardiovascular diseases

CVD is a key cause of death and disability among people across the world. The causes of cardiovascular disease are diverse and include smoking, diabetes, obesity, hyperlipidemia, and hypertension. Both type 1 diabetes and type 2 diabetes are often comorbid with CVD. Hyperglycemia induces oxidative stress, causes lipoprotein and endothelial dysfunction, and increases the risk of CVD.

Metformin, a common hypoglycemic drug, reduces the incidence of cardiovascular disease in people with diabetes. Metformin improves the level of endothelial oxidative stress and reduces hyperglycemia-induced inflammation, thereby reducing the incidence of CVD.

Existing Restraint

Increasing number of substitutes of metformin hydrochloride

The availability of various substitutes for metformin hydrochloride is expected to hamper the market. Metformin causes gastrointestinal side effects, hence people often switch to another drug. Januvia, Precose, Glucotrol XL, Actos, and Victoza are some substitutes for metformin. Metformin is used by patients with polycystic ovary syndrome to treat the associated insulin resistance.

Metformin does not suit every patient. Patients with a history of hypersensitivity reactions to metformin or biguanides cannot take metformin. Hence, they switch to the alternative treatment options of metformin.

Emerging Opportunity

Increasing incidence of obesity

Obesity has increased rapidly in recent years, due to lifestyle changes among people. Obesity is a chronic multifactorial disease with other associated metabolic syndromes such as diabetes, fatty liver disease, and cardiovascular disease. An imbalance between energy intake and expenditure causes obesity. Metformin is expected to be a potential treatment for obesity and its related metabolic disorders.

Metformin has weak but beneficial effects such as weight loss in people not affected by diabetes. In mice, metformin treatment for 14 weeks increased the gene expression of FGF21 (fibroblast growth factor 21). This key metabolic hormone promotes the lipolysis of white adipose tissue to prevent fat accumulation and prevents high-fat diet-induced obesity and associated inflammatory responses.

 Scope of Metformin Hydrochloride Market Report

The report on the global metformin hydrochloride market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Metformin Hydrochloride Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast

Base Year

2021

Historic Data

2019–2020

Forecast Period

2022–2030

Segmentation

Type (Metformin Hydrochloride-Immediate Release and Metformin Hydrochloride-Extended Release) and Distribution Channel (Hospital Pharmacy, Drug Store, Retail Pharmacy, and Online Pharmacy)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered

Dr. Reddy’s Laboratories Ltd.; Wanbury Ltd.; Cipla Inc.; Shandong Longze Chemical Co., Ltd.; Vistin Pharma AS; Shandong Keyuan Pharmaceutical Co., Ltd.; FARMHISPANIA Group; Harman Finochem Ltd; Aarti Drugs Ltd.; USV Private Limited.; Abhilasha Pharma Pvt. Ltd.; Bristol Laboratories Ltd; AdvaCare Pharma.; and Aurobindo Pharma USA

Metformin Hydrochloride Market Segment Insights

The global metformin hydrochloride market is segmented on the basis of type, distribution channel, and region.

Type Segment Analysis

Based on type, the metformin hydrochloride market is segmented into metformin hydrochloride-immediate release and metformin hydrochloride-extended release. The demand for metformin hydrochloride immediate-release is expected to rise at a substantial pace of 4.35%, due to its high adoption, to manage diabetes.

The usage of metformin hydrochloride immediate-release offers improved bioavailability and absorption and has an advanced wet granulation technique, which allows the uniform distribution of the drug.

Metformin Hydrochloride Market Type Segmentation

The metformin hydrochloride extended-release segment is projected to dominate the market, as metformin extended-release tablet offers several advantages for diabetic patients, such as improved patient compliance, and reduction in gastrointestinal side effects. Additionally, Glucophage XR is available in different doses, such as 500mg, 1,500 mg, and 2000mg, and is administered once a day for controlling blood glucose levels in type 2 diabetic patients. 

  • For instance, On December 21, 2022, Glenmark Pharmaceuticals Limited (Glenmark), a leading global pharmaceutical company launched the first triple fixed-dose combination of Teneligliptin with Pioglitazone and Metformin in India. Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor). This FDC has been launched under the brand name Zita-PioMet and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation. It helps to treat patients with type 2 diabetes with a daily dose of the tablet. It helps to improve glycemic and helps to control and achieve the targeted HbA1c within 24 weeks.

Distribution Channel Segment Analysis

In terms of distribution channel, the metformin hydrochloride market is segmented into hospital pharmacy, drug stores, retail pharmacy, and online pharmacy. The hospital pharmacy segment is expected to expand at a significant CAGR, owing to the increasing usage of metformin hydrochloride in hospital pharmacies. 

Metformin hydrochloride is prescribed in hospital pharmacies for hyperglycemia and polycystic ovary syndrome. 
The rising diabetes cases and awareness campaigns conducted for diabetic patients are projected to propel the growth of hospital pharmacies at a substantial pace.

Metformin Hydrochloride Market Distribution Segmentation

The retail pharmacy is expected to grow at a substantial rate, owing to rising investment in healthcare infrastructure and increasing awareness campaigns for diabetes, boosting the demand for metformin hydrochloride at retail pharmacies.

Regional Analysis

Based on region, the global metformin hydrochloride is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market for metformin hydrochloride in the Asia Pacific region is growing rapidly due to increased investment in the industrial sector and the growing population of the region.

The growth of the market in North America is attributed to the increasing number of people with diabetes and rising incidences of obesity caused by the adoption of an unhealthy diet. According to, Pan American Health Organization (PAHO), it is estimated that around 62 million people in Americas (422 million people worldwide) have diabetes, the majority living in low-and middle-income countries, and 284,049 deaths (1.5 million globally) are directly attributed to diabetes each year. 

  • For instance, the Centers for Disease Control and Prevention stated that there was around a 35% rise in cases of obesity among diabetic patients. Rising cases of obesity are boosting the demand for metformin hydrochloride in North America.

The presence of key manufacturers and their rising investments in the development of metformin hydrochloride tablets is projected to rise the consumption of diabetic drugs in Europe. According to data from IDF Diabetes Atlas 2021, revealed that The number of adults with diabetes is expected to reach 67 million by 2030 and 69 million by 2045 in Europe. The European Medicines Agency (EMA) has invested significantly in developing and assessing or testing metformin hydrochloride for type-2 diabetic patients, which is anticipated to boost the demand for metformin hydrochloride for type diabetes patients.

Metformin Hydrochloride Market Regions

Key Benefits for Industry Participants & Stakeholders

  • In-depth Analysis of the Global Metformin Hydrochloride Market
  • Historical, Current, and Projected Market Size in Terms of Value and Volume
  • Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
  • Industry Drivers, Restraints, and Opportunities Covered in the Study
  • Recent Industry Trends and Developments
  • Competitive Landscape & Strategies of Key Players
  • Neutral Perspective on Global Metformin Hydrochloride Market Performance

Segments

Type

  • Metformin Hydrochloride-Immediate Release
  • Metformin Hydrochloride-Extended Release

Distribution Channel

  • Hospital Pharmacy
  • Drug Store
  • Retail Pharmacy
  • Online Pharmacy

End-user

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Market Players Profiled in the Report

  • Dr. Reddy’s Laboratories Ltd.
  • Wanbury Ltd.
  • Cipla Inc.
  • Shandong Longze Chemical Co., Ltd.
  • Vistin Pharma AS
  • Shandong Keyuan Pharmaceutical Co., Ltd.
  • FARMHISPANIA Group
  • Harman Finochem Ltd
  • Aarti Drugs Ltd.
  • USV Private Limited.
  • Abhilasha Pharma Pvt. Ltd.
  • Bristol Laboratories Ltd
  • AdvaCare Pharma.
  • Aurobindo Pharma USA

Competitive Landscape

Key players operating in the market are Dr. Reddy’s Laboratories Ltd.; Wanbury Ltd.; Cipla Inc.; Shandong Longze Chemical Co., Ltd.; Vistin Pharma AS; Shandong Keyuan Pharmaceutical Co., Ltd.; FARMHISPANIA Group; Harman Finochem Ltd; Aarti Drugs Ltd.; USV Private Limited.; Abhilasha Pharma Pvt. Ltd.; Bristol Laboratories Ltd; AdvaCare Pharma.; Aurobindo Pharma USA. These companies are considered key manufacturers of Metformin Hydrochloride based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.

The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunities for the Metformin Hydrochloride market.

  • On, April 21, 2023, Dr. Reddy's Laboratories Ltd. and its subsidiaries launched Treprostinil injection in the U.S. The US Food and Drug Administration (USFDA) provides approval of the injection as a therapeutic equivalent generic version of Remodulin. The injection helps in relaxing blood vessels and increases the supply of blood to the lungs. Treprostinil injection is used for treating pulmonary arterial hypertension, to reduce the symptoms connected with exercise.
  • On October 04, 2021, Eli Lilly and Company (India) Pvt. Ltd., headquartered in Gurgaon, is a wholly-owned subsidiary of Eli Lilly and Company, headquartered in the USA, and Cipla Limited announced its strategic partnership in India to strengthen the reach of Lilly’s Diabetes products such as Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide). The agreement focuses on selling Lilly’s right in India to sell, distribute and promote the two diabetes medicines of Lilly to Cipla. Thereby, Cipla will boost its distribution strength and capabilities and increase access to these treatments for the needed patients.

Metformin Hydrochloride Market Key Players

Frequently Asked Questions

The Metformin Hydrochloride market was valued at USD 391.9 million in 2021 and is projected to reach USD 572.9 million by 2030, expanding at a CAGR of 4.4% during the forecast period.

Major players include Dr. Reddy’s Laboratories Ltd.; Wanbury Ltd.; Cipla Inc.; Shandong Longze Chemical Co., Ltd.; Vistin Pharma AS; Shandong Keyuan Pharmaceutical Co., Ltd.; FARMHISPANIA Group; Harman Finochem Ltd; Aarti Drugs Ltd.; USV Private Limited.; Abhilasha Pharma Pvt. Ltd.; Bristol Laboratories Ltd; AdvaCare Pharma.; Aurobindo Pharma USA

Factors such as Eco-friendly in nature, Urbanization, Industrial Infrastructure, Technological Advancement, and Demand for Metformin Hydrochloride are analyzed in the final report.

The major distribution channel for Metformin Hydrochloride is Hospital Pharmacies. Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.

The market is expected to witness considerable growth between 2019 and 2020 during the COVID 19 pandemic on the Metformin Hydrochloride market.

The base year considered for the Global Metformin Hydrochloride Market report is 2021. The complete analysis period is 2019 to 2030, wherein, 2019 and 2020 are the historic years, and the forecast is provided from 2022 to 2030.

The Metformin Hydrochloride market is projected to expand at a rapid pace globally, owing to the rising incidences of type-2 diabetes.

In addition to market size (in US$ Million), Company Market Share (in % for base year 2021), and quality parameter overview is provided.

Metformin hydrochloride reduces the rate of glucose released into the bloodstream from the liver and boosts the body’s glucose whereas, metformin is an ingredient of metformin hydrochloride.

SGLT-2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and others are the substitutes of metformin hydrochloride.

Table Of Content

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metformin Hydrochloride Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Metformin Hydrochloride Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Metformin Hydrochloride Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Metformin Hydrochloride Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Metformin Hydrochloride Market Size & Forecast, 2015-2030
      4.5.1 Metformin Hydrochloride Market Size and Y-o-Y Growth
      4.5.2 Metformin Hydrochloride Market Absolute $ Opportunity
   4.6 Global Metformin Hydrochloride Market: Impact Of Key Regulations
   4.7 Trend Outlook

Chapter 5 Global Metformin Hydrochloride Market Analysis and Forecast By Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Type
      5.1.2 Basis Point Share (BPS) Analysis By Type
      5.1.3 Absolute $ Opportunity Assessment By Type
   5.2 Metformin Hydrochloride Market Size Forecast By Type
      5.2.1 Metformin Hydrochloride-Immediate Release
      5.2.2 Metformin Hydrochloride-Extended Release
   5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Metformin Hydrochloride Market Analysis and Forecast By Distribution Channel
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Distribution Channel
      6.1.2 Basis Point Share (BPS) Analysis By Distribution Channel
      6.1.3 Absolute $ Opportunity Assessment By Distribution Channel
   6.2 Metformin Hydrochloride Market Size Forecast By Distribution Channel
      6.2.1 Hospital Pharmacy
      6.2.2 Drug Store
      6.2.3 Retail Pharmacy
      6.2.4 Online Pharmacy
   6.3 Market Attractiveness Analysis By Distribution Channel
Chapter 7 Global Metformin Hydrochloride Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Metformin Hydrochloride Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact
   8.1 Introduction
   8.2 Current & Future Impact Analysis
   8.3 Economic Impact Analysis
   8.4 Government Policies
   8.5 Investment Scenario
Chapter 9 North America Metformin Hydrochloride Analysis and Forecast
   9.1 Introduction
   9.2 North America Metformin Hydrochloride Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Metformin Hydrochloride Market Size Forecast By Type
      9.6.1 Metformin Hydrochloride-Immediate Release
      9.6.2 Metformin Hydrochloride-Extended Release
   9.7 Basis Point Share (BPS) Analysis By Type
   9.8 Absolute $ Opportunity Assessment By Type
   9.9 Market Attractiveness Analysis By Type
   9.10 North America Metformin Hydrochloride Market Size Forecast By Distribution Channel
      9.10.1 Hospital Pharmacy
      9.10.2 Drug Store
      9.10.3 Retail Pharmacy
      9.10.4 Online Pharmacy
   9.11 Basis Point Share (BPS) Analysis By Distribution Channel
   9.12 Absolute $ Opportunity Assessment By Distribution Channel
   9.13 Market Attractiveness Analysis By Distribution Channel
Chapter 10 Europe Metformin Hydrochloride Analysis and Forecast
   10.1 Introduction
   10.2 Europe Metformin Hydrochloride Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Metformin Hydrochloride Market Size Forecast By Type
      10.6.1 Metformin Hydrochloride-Immediate Release
      10.6.2 Metformin Hydrochloride-Extended Release
   10.7 Basis Point Share (BPS) Analysis By Type
   10.8 Absolute $ Opportunity Assessment By Type
   10.9 Market Attractiveness Analysis By Type
   10.10 Europe Metformin Hydrochloride Market Size Forecast By Distribution Channel
      10.10.1 Hospital Pharmacy
      10.10.2 Drug Store
      10.10.3 Retail Pharmacy
      10.10.4 Online Pharmacy
   10.11 Basis Point Share (BPS) Analysis By Distribution Channel
   10.12 Absolute $ Opportunity Assessment By Distribution Channel
   10.13 Market Attractiveness Analysis By Distribution Channel

Chapter 11 Asia Pacific Metformin Hydrochloride Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Metformin Hydrochloride Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Metformin Hydrochloride Market Size Forecast By Type
      11.6.1 Metformin Hydrochloride-Immediate Release
      11.6.2 Metformin Hydrochloride-Extended Release
   11.7 Basis Point Share (BPS) Analysis By Type
   11.8 Absolute $ Opportunity Assessment By Type
   11.9 Market Attractiveness Analysis By Type
   11.10 Asia Pacific Metformin Hydrochloride Market Size Forecast By Distribution Channel
      11.10.1 Hospital Pharmacy
      11.10.2 Drug Store
      11.10.3 Retail Pharmacy
      11.10.4 Online Pharmacy
   11.11 Basis Point Share (BPS) Analysis By Distribution Channel
   11.12 Absolute $ Opportunity Assessment By Distribution Channel
   11.13 Market Attractiveness Analysis By Distribution Channel
Chapter 12 Latin America Metformin Hydrochloride Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Metformin Hydrochloride Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Metformin Hydrochloride Market Size Forecast By Type
      12.6.1 Metformin Hydrochloride-Immediate Release
      12.6.2 Metformin Hydrochloride-Extended Release
   12.7 Basis Point Share (BPS) Analysis By Type
   12.8 Absolute $ Opportunity Assessment By Type
   12.9 Market Attractiveness Analysis By Type
   12.10 Latin America Metformin Hydrochloride Market Size Forecast By Distribution Channel
      12.10.1 Hospital Pharmacy
      12.10.2 Drug Store
      12.10.3 Retail Pharmacy
      12.10.4 Online Pharmacy
   12.11 Basis Point Share (BPS) Analysis By Distribution Channel
   12.12 Absolute $ Opportunity Assessment By Distribution Channel
   12.13 Market Attractiveness Analysis By Distribution Channel
Chapter 13 Middle East & Africa (MEA) Metformin Hydrochloride Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Metformin Hydrochloride Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Metformin Hydrochloride Market Size Forecast By Type
      13.6.1 Metformin Hydrochloride-Immediate Release
      13.6.2 Metformin Hydrochloride-Extended Release
   13.7 Basis Point Share (BPS) Analysis By Type
   13.8 Absolute $ Opportunity Assessment By Type
   13.9 Market Attractiveness Analysis By Type
   13.10 Middle East & Africa (MEA) Metformin Hydrochloride Market Size Forecast By Distribution Channel
      13.10.1 Hospital Pharmacy
      13.10.2 Drug Store
      13.10.3 Retail Pharmacy
      13.10.4 Online Pharmacy
   13.11 Basis Point Share (BPS) Analysis By Distribution Channel
   13.12 Absolute $ Opportunity Assessment By Distribution Channel
   13.13 Market Attractiveness Analysis By Distribution Channel

Chapter 14 Competition Landscape
   14.1 Metformin Hydrochloride Market: Competitive Dashboard
   14.2 Global Metformin Hydrochloride Market: Market Share Analysis, 2021
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      14.3.1 Wanbury
      14.3.2 Shandong Longze Chemical Co.,Ltd.
      14.3.3 Vistin Pharma AS
      14.3.4 Shandong Keyuan Pharmaceutical Co., Ltd.
      14.3.5 Farmhispania Group
      14.3.6 Harman Finochem Ltd
      14.3.7 Aarti Drugs
      14.3.8 Dr. Reddy’s Laboratories Ltd.
      14.3.9 USV Pvt Ltd
      14.3.10 Abhilasha Pharma
      14.3.11 Bristol Laboratories Ltd
      14.3.12 AdvaCare Pharma
      14.3.13 Cipla
      14.3.14 Aurobindo Pharma USA

Methodology

Our Clients

Siemens Healthcare
Microsoft
Dassault Aviation
Nestle SA
General Electric
General Mills
The John Holland Group
FedEx Logistics